The CARDERA trial randomized 467 early active RA patients to receive : ( 1 ) methotrexate , ( 2 ) methotrexate/ciclosporin , ( 3 ) methotrexate/prednisolone or ( 4 ) methotrexate/ciclosporin/prednisolone in a factorial-design .